Physician profile
Razi Hasan
NPI 1467533364
$3,129.99
in general payments reported to CMS, 2019-2025
14 companies · $627 in 2025
The $627 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $232 · 2021: $64.32 · 2022: $375 · 2023: $559 · 2024: $584 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $799.59 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $748.75 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $402.94 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $391.34 | 2023-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $310.86 | 2019-2025 | Adzenys Xr-Odt, Metadate Cd |
| Otsuka America Pharmaceutical, INC. | $159.77 | 2021-2023 | Abilify Mycite |
| Collegium Pharmaceutical, INC. | $70.94 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $55.03 | 2019-2025 | Verquvo |
| Shire North American Group INC | $49.39 | 2019 | |
| Avion Pharmaceuticals | $40.96 | 2023-2024 | Methylphenidate Hydrochloride |
| Pfizer INC. | $37.98 | 2019-2024 | |
| Verrica Pharmaceuticals INC. | $24.52 | 2024 | Ycanth |
| Vertical Pharmaceuticals, LLC | $19.95 | 2024 | Relexxii |
| Cranial Technologies, INC | $17.97 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Razi Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.